ProfileGDS5678 / 1442186_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 28% 28% 29% 30% 30% 27% 27% 29% 32% 30% 45% 28% 29% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6679528
GSM967853U87-EV human glioblastoma xenograft - Control 22.6422428
GSM967854U87-EV human glioblastoma xenograft - Control 32.6521229
GSM967855U87-EV human glioblastoma xenograft - Control 42.6418730
GSM967856U87-EV human glioblastoma xenograft - Control 52.6383230
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6970827
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6671927
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6512929
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6987232
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6628730
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0505245
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6176728
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6672529
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9952343